Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib in High-Grade Uterine Cancers
NCT00231829Phase 2Terminated
- Start
- Apr 2003
- Primary completion
- Mar 2004
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of celecoxib in uterine cancer. Primary endpoint: COX-II expression in uterine cancers. Started Apr 2003; status: terminated.
02
Drugs
celecoxib
03
Conditions
uterine cancer
Beyond the preview
Go deeper on NCT00231829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231829.